BOSTON, May 28, 2025 -- Aktis Oncology, Inc., an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced...
Liquidia Announces Product Development Collaboration with GSK
News | 06. 20. 2012
RESEARCH TRIANGLE PARK, NC– June 20, 2012 -‐ Liquidia Technologies today announced the initiation of a broad, multi-‐year collaboration with GlaxoSmithKline (GSK), which has acquired exclusive rights to research and develop certain vaccine and inhaled product candidates using the company’s proprietary PRINT® (Particle Replication In Non-‐Wetting Templates) technology. Liquidia’s PRINT technology is a powerful and versatile nanoparticle technology product development and manufacturing platform that is changing the way companies engineer healthcare products.
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.